Skip to main content
Modalis Therapeutics Corporation logo

Modalis Therapeutics Corporation — Investor Relations & Filings

Ticker · 4883 ISIN · JP3922600006 T Manufacturing
Open in API
Filings indexed 57 across all filing types
Latest filing 2023-11-13 Report Publication Anno…
Country JP Japan
Listing T 4883

About Modalis Therapeutics Corporation

https://modalistx.com/en/

Modalis Therapeutics Corporation is a biotechnology company developing precision genetic medicines for serious disorders. The company's core technology is CRISPR-GNDM®, a proprietary epigenome editing platform. This technology regulates the expression of specific genes—selectively activating or suppressing them—without altering the underlying DNA sequence or causing double-strand breaks. CRISPR-GNDM® utilizes a compact epigenome editor designed for efficient delivery to target cells using adeno-associated virus (AAV) vectors. The company advances its programs through a hybrid model of in-house development and collaborative partnerships, with a pipeline focused on therapeutic areas such as muscular disorders, cardiomyopathy, and central nervous system (CNS) disorders.

Recent filings

Filing Released Lang Actions
確認書
Report Publication Announcement Classification · 100% confidence The document is a 'Confirmation Letter' (Kakunin-sho) filed under the Financial Instruments and Exchange Act in Japan. It specifically confirms the accuracy of the contents of a Quarterly Report (Shihanki Hokokusho) for the third quarter of the 8th fiscal period. Since this is a formal regulatory filing confirming the validity of financial reporting rather than the financial report itself, and it does not fit into the specific categories of AGM, dividend, or share transactions, it is classified as a Regulatory Filing (RNS).
2023-11-13 Japanese
四半期報告書－第8期第3四半期(2023/07/01－2023/09/30)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) filed by Modalis Therapeutics Corporation in Japan. It contains detailed financial statements, management analysis (MDA), and corporate information for the third quarter of the fiscal year 2023. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). 9M 2023
2023-11-13 Japanese
確認書
Regulatory Filings Classification · 95% confidence The document is a 'Confirmation Letter' (確認書) filed under the Financial Instruments and Exchange Act in Japan. It serves as an officer certification by the CEO and CFO confirming the accuracy of the company's quarterly report. Per the 'CERTIFICATION RULE', documents that are primarily officer certifications or attestations, even if they reference a specific report type (like a quarterly report), should be classified as Regulatory Filings (RNS) rather than the report itself. Q2 8
2023-08-14 Japanese
四半期報告書－第8期第2四半期(2023/04/01－2023/06/30)
Interim / Quarterly Report Classification · 100% confidence The document is a '四半期報告書' (Quarterly Report) filed with the Kanto Local Finance Bureau in Japan, as indicated by the header and the legal basis (Financial Instruments and Exchange Act). It contains comprehensive financial statements, management analysis (MDA), and details on shareholding and business operations for the second quarter of the 8th fiscal period (April 1, 2023, to June 30, 2023). This fits the definition of an Interim/Quarterly Report (IR). Q2 2023
2023-08-14 Japanese
確認書
Report Publication Announcement Classification · 100% confidence The document is a 'Confirmation Letter' (Kakunin-sho) filed under the Financial Instruments and Exchange Act in Japan. It is a mandatory regulatory filing that accompanies a quarterly report, where the CEO and CFO certify the accuracy of the report's contents. Since it is a specific regulatory filing required by law that does not fit into the categories of the report itself (IR) or a simple announcement (RPA), it falls under the general regulatory filings category.
2023-05-12 Japanese
四半期報告書－第8期第1四半期(2023/01/01－2023/03/31)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) filed by Modalis Therapeutics Corporation with the Kanto Local Finance Bureau. It contains detailed financial statements, including the balance sheet and income statement for the first quarter of the 8th fiscal year (January 1, 2023, to March 31, 2023). It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). Q1 2023
2023-05-12 Japanese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.